NAV
$31.62
AUM
$10.3M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.80
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +3.76% | +10.56% | +9.50% | +27.59% | +8.82% | +0.69% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | GILD | Gilead Sciences Inc | 5.42% |
| 2 | MRK | Merck & Co Inc | 5.17% |
| 3 | JNJ | Johnson & Johnson | 5.15% |
| 4 | EW | Edwards Lifesciences Corp | 4.79% |
| 5 | XTSLA | BlackRock Cash Funds Treasury SL Agency | 4.64% |
| 6 | WAT | Waters Corp | 3.84% |
| 7 | BIIB | Biogen Inc | 3.67% |
| 8 | BRKR | Bruker Corp | 3.64% |
| 9 | AMGN | Amgen Inc | 3.41% |
| 10 | 2269.HK | WuXi Biologics (Cayman) Inc | 3.13% |
Under normal market conditions, the fund will invest at least 80% of its net assets plus any borrowings for investment purposes in equity securities of companies principally engaged in the health sciences group of industries. While the fund will invest primarily in companies providing products and services for human health, it may also invest in companies whose products or services relate to the growth or survival of animals and plants.
Inception Date: 2020-09-29